卵巢肿瘤增殖细胞核抗原的表达及意义  

The Expression of PCNA in Ovarian Tumor and Its Clinical Significance

作　　者：袁碧波[1] 刘姝华[2] 张士伟[2] 陈斌其 

机构地区：[1]天津医科大学第二医院妇科,300052 [2]天津医科大学总医院妇科,300052

出　　处：《天津医药》1999年第12期731-733,共3页Tianjin Medical Journal

摘　　要：研究增殖细胞核抗原（ＰＣＮＡ）在卵巢肿瘤中的表达及意义。方法：应用免疫组化ＡＢＣ法检测１３３例卵巢肿瘤和１２例正常卵巢组织ＰＣＮＡ的表达。结果：卵巢肿瘤与正常卵巢组织的ＰＣＮＡ表达有显著性差异。良性、交界性、恶性组 ＰＣＮＡ表达呈上升趋势（Ｐ＜ ０．０５）。病理分类上皮性组 ＰＣＮＡ表达显著高于非上皮性组（Ｐ＜０．０５）。在上皮性组中，中、低分化组ＰＣＮＡ表达高于高分化组，晚期表达高于早期（Ｐ＜０．０５），ＰＣＮＡ表达与残存癌灶大小及淋巴结转移无关（Ｐ＞０．０５）。对患者生存期的分析表明，ＰＣＮＡ尚不能作为卵巢癌的独立预后判断因素。结论：卵巢肿瘤存在着细胞增殖活性的差异，细胞的过度增殖在卵巢癌的发生、发展中起一定作用。测定卵巢肿瘤ＰＣＮＡ的表达，对正确评价肿瘤的组织学分级有一定指导价值，并有助于筛选高危患者，指导“个体化”治疗。Objective: To study the expression of proliferative cell nucleus antigen (PCNA) in ovarian tumor and its clinical significance. Metheds:The expression of PCNA was investigated in 133 cases of ovarian tumor (OT) and 12 normal ovarian tissues (Not) by immunohistochemistry techniques. Results:The expression of PCNA had significant differences between OT and Not (P<0 .001). The expression of PCNA in benign ovarian tumor (BOT),borderline ovarian tumor (BLOT) and malignant ovarian tumor (MOT) had an ascent tendency (P<0.05). The expression of PCNA in EOT was higher than those in non-epithelial ovarian tumor (NEOT) (P< 0 .05). In EOT group, the expression of PCNA in G2,G3 or advanced stage were higher than those in G1 or early stage (P< 0.05, respeively). No relationships between expression of PCNA and residual carcinoma (RC) or lymphaden metastasis (LPM) were found, P >0 .05. Survial analysis revealed PCNA could not be a cell prognostic factor of ovarian tumor. Conclusion: The differences of cell proliferation activity existed among ovarian tumors. Uncontrolled cell proliferation played a role in the genesis and progression of ovarian carcinoma. The expression of PCNA negatively correlated with differentiation. As an objective index, it was helpful in evaluating differentiation and in choosing high risk patients and conducting individual therapy.

关 键 词：卵巢肿瘤 增殖细胞核抗原 免疫组织化学 

分 类 号：R737.31[医药卫生—肿瘤]